MOLECULAR AND SPATIAL CHARACTERIZATION OF DRUG RESISTANCE IN HUMAN OVARIAN CANCER
Grant number: 1161198 | Funding period: 2019 - 2021
Ovarian cancer is the most deadly gynecologic cancer in Western women. Although initially responsive to chemotherapy, drug resistance commonly evolves in a matter of months. We previously documented novel mechanisms of drug resistance in the most common form of ovarian cancer and in this study we will map their distribution within patients. We will also investigate mechanisms of resistance to a new important class of anti-cancer drugs in ovarian cancer, the PARP inhibitors.
Related publications (1)
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...